SE1146865T5 - - Google Patents

Info

Publication number
SE1146865T5
SE1146865T5 SE99902781T SE99902781T SE1146865T5 SE 1146865 T5 SE1146865 T5 SE 1146865T5 SE 99902781 T SE99902781 T SE 99902781T SE 99902781 T SE99902781 T SE 99902781T SE 1146865 T5 SE1146865 T5 SE 1146865T5
Authority
SE
Sweden
Prior art keywords
sotalol
antiarrhythmic
laevo
dextro
ratio
Prior art date
Application number
SE99902781T
Other languages
English (en)
Other versions
SE1146865T3 (zh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of SE1146865T3 publication Critical patent/SE1146865T3/xx
Publication of SE1146865T5 publication Critical patent/SE1146865T5/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE99902781T 1999-02-05 1999-02-22 SE1146865T5 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN89KO1999 IN188162B (zh) 1999-02-05 1999-02-05

Publications (2)

Publication Number Publication Date
SE1146865T3 SE1146865T3 (zh) 2003-09-02
SE1146865T5 true SE1146865T5 (zh) 2003-11-18

Family

ID=38668683

Family Applications (1)

Application Number Title Priority Date Filing Date
SE99902781T SE1146865T5 (zh) 1999-02-05 1999-02-22

Country Status (20)

Country Link
US (1) US6281246B2 (zh)
EP (1) EP1146865B9 (zh)
JP (1) JP2002536324A (zh)
CN (1) CN1149987C (zh)
AT (1) ATE241349T1 (zh)
AU (1) AU761521C (zh)
BR (1) BR9915951A (zh)
CA (1) CA2348882C (zh)
CZ (1) CZ20011807A3 (zh)
DE (1) DE69908421T2 (zh)
DK (1) DK1146865T3 (zh)
ES (1) ES2195538T3 (zh)
HK (1) HK1041206B (zh)
HU (1) HU224033B1 (zh)
IN (1) IN188162B (zh)
PL (1) PL351143A1 (zh)
PT (1) PT1146865E (zh)
RU (1) RU2213560C2 (zh)
SE (1) SE1146865T5 (zh)
WO (1) WO2000045807A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105044A1 (en) 2004-05-20 2006-05-18 Singh Bramah N Sustained release formulations of sotalol
CN101448784B (zh) * 2006-05-18 2012-07-04 冬姆佩股份公司 (2r)-2-[(4-磺酰基)氨基苯基]丙酰胺及含有它们的药物组合物
CN102329254B (zh) * 2010-07-12 2014-02-05 上海奥博生物医药技术有限公司 一种制备n-[4-[1-羟基-2-[(1-甲基乙基)胺基]乙基]甲磺酰胺盐酸盐的方法
BE1021320B1 (fr) * 2014-08-27 2015-10-29 Hyloris Pharmaceuticals SA Composition pharmaceutique prete a l'emploi
BE1021328B1 (fr) * 2014-08-27 2015-10-30 Hyloris Pharmaceuticals SA Composition pharmaceutique prete a l'emploi
FR3050297A1 (fr) * 2016-04-13 2017-10-20 Assist Publique - Hopitaux De Paris Methode de determination de la susceptibilite d'induction d'une torsade de pointes
CN109419780B (zh) * 2017-09-04 2021-05-11 张家港市中医医院 一种盐酸索他洛尔片剂及其制备方法
CN109419779B (zh) * 2017-09-04 2021-05-25 鲁南制药集团股份有限公司 一种盐酸索他洛尔制剂
CN107982237B (zh) * 2018-01-17 2018-11-23 安宁 一种盐酸索他洛尔制剂及其制备方法
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089526A (en) * 1983-05-23 1992-02-18 Bristol-Myers Company Antiarrhythmic class III process
JPH01165569A (ja) * 1987-12-22 1989-06-29 Mitsui Toatsu Chem Inc 光学活性なソタロールの製造方法
IES61567B2 (en) * 1994-02-17 1994-11-16 Russinsky Ltd Pharmaceutical products

Also Published As

Publication number Publication date
RU2213560C2 (ru) 2003-10-10
CZ20011807A3 (cs) 2001-08-15
HUP0104175A2 (hu) 2002-04-29
DE69908421D1 (de) 2003-07-03
SE1146865T3 (zh) 2003-09-02
CN1149987C (zh) 2004-05-19
AU761521B2 (en) 2003-06-05
CA2348882A1 (en) 2000-08-10
EP1146865A1 (en) 2001-10-24
BR9915951A (pt) 2001-08-21
HU224033B1 (hu) 2005-05-30
ATE241349T1 (de) 2003-06-15
AU761521C (en) 2004-01-22
HK1041206A1 (en) 2002-07-05
JP2002536324A (ja) 2002-10-29
AU2296099A (en) 2000-08-25
PL351143A1 (en) 2003-03-24
CN1328453A (zh) 2001-12-26
DK1146865T3 (da) 2003-09-22
EP1146865B1 (en) 2003-05-28
CA2348882C (en) 2004-07-13
EP1146865B9 (en) 2004-03-17
PT1146865E (pt) 2003-08-29
HUP0104175A3 (en) 2002-12-28
ES2195538T3 (es) 2003-12-01
DE69908421T2 (de) 2004-03-18
HK1041206B (zh) 2003-10-31
WO2000045807A1 (en) 2000-08-10
US20010004643A1 (en) 2001-06-21
US6281246B2 (en) 2001-08-28
IN188162B (zh) 2002-08-31

Similar Documents

Publication Publication Date Title
SE1146865T3 (zh)
ES8505519A1 (es) Un procedimiento para la preparacion de 14-fluoromorfinanos utiles como analgesicos, narcoticos y-o agentes anorexicos.
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
BR0111207A (pt) Combinações de um antagonista receptor de endotelina e um composto antiepiléptico tendo propriedades de alìvio da dor ou analgésicos
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
IL143901A0 (en) Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
AU5090796A (en) Use of dextromethorphan or dextrorphan for the treatment of urinary incontinence
BRPI0314308B8 (pt) antagonistas de opióide, seus usos, e composição farmacêutica
CO5271710A1 (es) Combinanciones de un inhibidor de cinasa de tirosina receptora con un compuesto organico capaz de enlazarse con glicorpoteina acido-a
CA2408417A1 (en) Local anesthetic methods and kits
RU99107280A (ru) Фармацевтический препарат для лечения гипертрофии простаты и рака простаты и способ лечения
UA70919C2 (uk) Композиція для лікування та запобігання артеріальному тромбозу з використанням інгібітора фактора ха окремо або в комбінації з препаратом, що унеможливлює агрегацію тромбоцитів
Leal et al. Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-D-aspartate receptors
HUT74948A (en) Use of p antagonist for producing pharmaceutical compositions for treating acne, rosacea and/or pubic arythema
NO20020731D0 (no) Kosttilskudd for å forbedre den muskul¶re energimetabolismen som innbefatter en alkanoylkarnitin og ribose
Gaggi et al. Effects of calcium antagonists on biogenic amines in discrete brain areas
NZ506529A (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (LT) pathway
Taber et al. Antagonism of the analgesic effect of opioid and non-opioid agents by p-chlorophenylalanine (PCPA)
BR0008057A (pt) Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada
Kimoto et al. Effects of [1-desamino-8-D-arginine] vasopressin and papaverine on rabbit renal pelvis
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
Fisher et al. Effects of glutamate antagonists on the activity of aromatic L-amino acid decarboxylase
Chipkin et al. Determination of analgesic drug efficacies by modification of the Randall and Selitto rat yeast paw test
KANETO et al. Morphine analgesia without development of tolerance in reserpinized mice
Ha et al. The action of diazepam in the isolated rat detrusor muscle